TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

Br J Dermatol 2004;151:1096-100.
11B.39 Adékambi T. Mycobacterium mucogenicum group infection: a review. Clin Microbiol Infect 2009;15:
911-8.
11B.40 Lindeboom JA et al. Cervicofacial lymphadenitis in children caused by Mycobacterium haemophilum.
Clin Infect Dis 2005;41:1569-75.
11B.41 Fairhurst RM et al. Mycobacterium haemophilum infections in heart transplant recipients: case report
and review of the literature. Am J Transplant 2002;2:476-9.
11B.42 Stürenberg E et al. Disseminated Mycobacterium haemophilum infection as initial manifestation of
AIDS. Tuberculosis 2004;84:341-5.
11B.43 Lindeboom JA et al. Surgical excision versus antibiotic treatment for cervical nontuberculous mycobacterial
lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis 2007;
44:1057-64.
11B.44 Griffith DE et al. Thrice weekly clarithromycin containing regimen for treatment of Mycobacterium kansasii
lung disease: results of a preliminary study. Clin Infect Dis 2003;37:1178-82.
11B.45 Brown-Elliott BA et al. In vitro activity of linezolid against slowly growing non tuberculous mycobacteria.
Antimicrob Agents Chemother 2003;47:1736-8.
11B.46 Guna R et al. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of
Mycobacterium kansasii. J Antimicrob Chemother 2005;55:950-3.
11B.47 Alcaide F et al. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin,
moxifloxacin and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob
Agents Chemother 2004;48:4562-5.
11B.48 Pardillo FE et al. Methods for the classification of leprosy for treatment purposes. Clin Infect Dis
2007;44:1096-9.
11B.49 Britton WJ et al. Leprosy. Lancet 2004;363:1209-19.
11B.50 Scollard DM et al. The continuing challenges of leprosy. Clin Microbiol Rev 2006;19:338-81.
11B.51 Agrawal A et al. Neurological manifestations of Hansen‘s disease and their management. Clin Neurol
Neurosurg 2005;107:445-54.
11B.52 Moschella SL. An update on the diagnosis and treatment of leprosy. J Am Acad Dermatol 2004;51:
417-26.
11B.53 Petrini B. Mycobacterium marinum: ubiquitous agent of waterborne granulomatous skin infections.
Eur J Clin Microbiol Infect Dis 2006;25:609-13.
11B.54 Ang P et al. Retrospective study of Mycobacterium marinum skin infections. Int J Dermatol 2000;39:
343-7.
11B.55 Bhatty MA et al. Mycobacterium marinum hand infection: case reports and review of literature. Br J
Plast Surg 2000;53:161-5.
11B.56 Jernigan JA et al. Incubation period and sources of exposure for cutaneous Mycobacterium marinum
infection: case report and review of the literature. Clin Infect Dis 2000;31:439-43.
11B.57 Hess CL et al. Mycobacterium marinum infections of the upper extremity. Plast Reconstruct Surg
2005;115:55e-9e.
11B.58 Oliver JD. Wound infections caused by Vibrio vulnificus and other marine bacteria. Epidemiol Infect
2005;133:383-91.
11B.59 Bråbäck M et al. Susceptibilities of Mycobacterium marinum to gatifloxacin, gemifloxacin, levofloxacin,
linezolid, moxifloxacin, telithromycin and quinupristin-dalfopristin compared to its susceptibilities
to reference macrolides and quinolones. Antimicrob Agents Chemother 2002;46:1114-6.
11B.60 Patel NC et al. Mycobacterium simiae cervical lymphadenitis. Pediatr Infect Dis J 2007;26:362-3.
11B.61 Al-Abdely HM et al. Disseminated Mycobacterium simiae infection in patients with AIDS. J Infect
2000;41:143-7.
11B.62 Safdar A et al. Mycobacterium lentiflavum, a recently identified slow-growing mycobacterial species:
clinical significance in immunosuppressed cancer patients and summary of reported cases of infection.
Eur J Clin Microbiol Infect Dis 2005;24:554-8.
11B.63 Walsh DS et al. Buruli Ulcer (Mycobacterium ulcerans infection): a re-emerging disease. Clin Microbiol
Newslett 2009;31:119-27.
11B.64 O‘Brien DP et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic
therapy: findings from a south-eastern Australian case series. Med J Aust 2007;186:58-61.
11B.65 Wansbrough-Jones M et al. Buruli ulcer: emerging from obscurity. Lancet 2006;367:1849-58.
11B.66 Sizaire V et al. Mycobacterium ulcerans infection: control, diagnosis, and treatment. Lancet Infect
Dis 2006;6:288-96.
11B.67 Ji B et al. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910,
linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 2006;50:
1921-6.
11B.68 Wansbrough-Jones M et al. Buruli ulcer. A neglected but treatable disease that unnecessarily scars
African children for life. Br Med J 2005;330:1402-3.
11B.69 Etuaful S et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium
ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005;49:
3182-6.
11B.70 Sizaire V et al. Mycobacterium ulcerans infection: control, diagnosis and treatment. Lancet Infect Dis
2006;6:288-96.
11B.71 van der Werf TS et al. Mycolactones and Mycobacterium ulcerans disease. Lancet 2003;362:1062-4.
11B.72 Thangaraj HS et al. Emerging aspects of Buruli ulcer. Expert Rev Anti Infect Ther 2003;1:217-22.
11B.73 Wansbrough-Jones M et al. Buruli ulcer: emerging from obscurity. Lancet 2006;367:1849-58.
11B.74 van der Werf TS et al. Mycobacterium ulcerans disease. Bull World Health Organ 2005;83:785-91.
11B.75 van Ingen J et al. Mycobacterium xenopi clinical relevance and determinants, the Netherlands.
Emerg Infect Dis 2008;14:385-9.
11B.76 Jenkins PA et al. Pulmonary disease caused by Mycobacterium xenopi in HIV negative patients: five
year follow-up of patients receiving standardised treatment. Respir Med 2003;97:439-44.
11B.77 Kerbiriou L et al. Human immunodefiency virus type 1 related Mycobacterium xenopi infection: a need
to treat? Clin Infect Dis 2003;37:1250-4.
11B.78 Lounis N et al. Efficacies of clarithromycin regimens against Mycobacterium xenopi in mice. Antimi-